Shares of Apellis Pharmaceuticals Inc. jumped 16.8% in premarket trading on Friday after the company said the Food and Drug Administration accepted an amendment to its drug-approval submission for a geographic atrophy therapy. The FDA is expected to make a decision on the drug by Feb. 26, and the company said the regulator does not plan to hold an advisory committee meeting to discuss the new drug application for pegcetacoplan. Apellis’ stock has declined 33.9% over the last three months, while the broader S&P 500 is down 7.6%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.